Computational reconstruction of disease pathways

Information

  • Research Project
  • 6934045
  • ApplicationId
    6934045
  • Core Project Number
    R43GM070219
  • Full Project Number
    1R43GM070219-01A2
  • Serial Number
    70219
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/2005 - 19 years ago
  • Project End Date
    11/30/2006 - 18 years ago
  • Program Officer Name
    HEATH, ANNE K
  • Budget Start Date
    6/1/2005 - 19 years ago
  • Budget End Date
    11/30/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    5/12/2005 - 20 years ago
Organizations

Computational reconstruction of disease pathways

DESCRIPTION (provided by applicant): We propose to develop technology for an automated functional analysis of large sets of high-throughput molecular data in the framework of human pathways. Our approach will allow rapid reconstruction of unique pathway/network motifs that closely correlate with given condition, disease or phenotype ("signature networks"). Such networks could then serve as means for finding/validating drug targets and biomarkers, predicting response to a treatment and designing a new generation of diagnostic tools. In phase I, we will develop several algorithms and prototype software for automated reconstruction of such condition-specific pathways. We will test and validate developed algorithms using large set of high quality microarray data from myeloma cell lines obtained by our collaborators at Van Andel Research Institute (VARI). In phase II developed algorithms will be applied to various sets of molecular data obtained from clinical samples available at VARI (approximately 1,000 samples) and further refined for reconstruction of disease "signature networks". Commercial potential of the research will be realized through three major channels: 1) developing new analytical modules for our existing MetaCore(tm) platform; 2) generating intellectual property by analyzing data from clinical samples in collaboration with Van Andel Research Institute; 3) entering into collaborative agreements with major drug companies for the expert analysis of in-house data.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99324
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:99324\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GENEGO, INC.
  • Organization Department
  • Organization DUNS
    113429489
  • Organization City
    ST. JOSEPH
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    49085
  • Organization District
    UNITED STATES